Stoke Therapeutics Receives Authorization to Initiate a Phase 1/2 Study of STK-002 for Autosomal Dominant Optic Atrophy (ADOA) in the United KingdomBusiness Wire • 04/25/23
Stoke Therapeutics Announces That FDA Will Allow the Administration of a Higher Single Dose of STK-001 (70mg) in the Ongoing Phase 1/2a MONARCH Study of Children and Adolescents with Dravet SyndromeBusiness Wire • 03/15/23
Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 03/06/23
Stoke Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business UpdatesBusiness Wire • 03/06/23
Stoke Therapeutics to Present at the SVB Securities Global Biopharma ConferenceBusiness Wire • 02/07/23
Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2023Business Wire • 01/09/23
Stoke Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/04/23
Stoke Therapeutics Presents Data from a Combined Interim Analysis of the Phase 1/2a MONARCH and ADMIRAL Studies of STK-001 in Children and Adolescents with Dravet Syndrome at the American Epilepsy Society (AES) 2022 Annual MeetingBusiness Wire • 12/02/22
Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Program at the American Epilepsy Society 2022 Annual MeetingBusiness Wire • 11/29/22
Buy Stoke Therapeutics At A Deep Discount Following Early Data In Dravet SyndromeSeeking Alpha • 11/28/22
Stoke Therapeutics, Inc. (STOK) Reports Q3 Loss, Tops Revenue EstimatesZacks Investment Research • 11/14/22
Is a Surprise Coming for Stoke Therapeutics (STOK) This Earnings Season?Zacks Investment Research • 11/10/22
Stoke Therapeutics to Host Webinar and Conference Call to Present Interim Data from the Phase 1/2a Studies of STK-001 in Children and Adolescents with Dravet SyndromeBusiness Wire • 11/10/22
Stoke Therapeutics, Inc. (STOK) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 11/07/22
Moore Kuehn, PLLC Encourages Investors of Stoke Therapeutics, Inc. to Contact Law FirmPRNewsWire • 10/18/22
Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)Business Wire • 08/25/22
How Much Upside is Left in Stoke Therapeutics, Inc. (STOK)? Wall Street Analysts Think 91%Zacks Investment Research • 08/10/22
Stoke Therapeutics Presents New In-Vivo Data That Demonstrated Dose-Related Target Engagement and OPA1 Protein Upregulation in Retinal Tissue Following Administration of STK-002Business Wire • 05/02/22
Stoke Therapeutics to Present at The Association for Research in Vision and Ophthalmology (ARVO) 2022 Annual MeetingBusiness Wire • 04/07/22